ライフサイエンスコーパス: linagliptin

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 2:1 ratio to once-daily oral treatment with linagliptin 5 mg or matching placebo for 24 weeks.

2 nity-living outpatients were randomised (162 linagliptin, 79 placebo).

3 We aimed to assess the effectiveness of linagliptin, a dipeptidyl peptidase-4 inhibitor, in elde

4 tolerability were much the same between the linagliptin and placebo groups; 75.9% of patients in bot

5 Mice were treated with linagliptin/glimepiride for 7 weeks.

6 nts occurred in 8.6% (14) of patients in the linagliptin group and 6.3% (five) patients in the placeb

7 not differ between groups (24.1% [39] in the linagliptin group, 16.5% [13] in the placebo group; odds

8 Previous studies have shown linagliptin improves beta cell function using animal mod

9 abetic islets, suggesting a positive role of linagliptin in modulating alpha cell function to restore

10 We show pronounced antistroke efficacy of linagliptin in type 2 diabetic and normal mice, whereas

11 termine the potential antistroke efficacy of linagliptin in type 2 diabetic mice.

12 Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibito

13 Linagliptin is a dipeptidyl Peptidase-4 (DPP-4) inhibito

14 To determine whether linagliptin-mediated efficacy was dependent on a diabeti

15 These results indicate a linagliptin-mediated neuroprotection that is glucose-ind

16 atients in both groups had an adverse event (linagliptin n=123, placebo n=60).

17 Our data showed that linagliptin significantly improved glucose-stimulated in

18 mediates in the lead optimization program of linagliptin, the onset of slow binding kinetics and deve

19 In addition, linagliptin treatment increased the relative GLP-1 vs gl

20 uman islets of T2D patients would respond to linagliptin treatment.

21 hout T2D and evaluated how they responded to linagliptin treatment.

22 , placebo-adjusted mean change in HbA1c with linagliptin was -0.64% (95% CI -0.81 to -0.48, p<0.0001)

23 In elderly patients with type 2 diabetes linagliptin was efficacious in lowering glucose with a s

24 from the standpoint of islet cell function, linagliptin would be more effective in treating early-st

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。